Related references
Note: Only part of the references are listed.Treatment of Advanced Melanoma in 2020 and Beyond
Russell W. Jenkins et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
A. Gault et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Julia Maria Ressler et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Safety of topical interventions for the treatment of actinic keratosis
Elias A. T. Koch et al.
EXPERT OPINION ON DRUG SAFETY (2021)
Recent advancements in melanoma management
Tharani Krishnan et al.
INTERNAL MEDICINE JOURNAL (2021)
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries
Avirup Guha et al.
CANCER MEDICINE (2021)
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Pier Francesco Ferrucci et al.
CANCERS (2021)
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
Julian Steininger et al.
CANCERS (2021)
Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review
Kerianne Boulva et al.
CANCERS (2021)
Looking into a Better Future: Novel Therapies for Metastatic Melanoma
Alessia Villani et al.
DERMATOLOGY AND THERAPY (2021)
Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines
Kue Peng Lim et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Advances in the discovery and development of melanoma drug therapies
Monica Chanda et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Principles of Targeted Therapy for Melanoma
James Sun et al.
SURGICAL CLINICS OF NORTH AMERICA (2020)
Management of Locoregionally Advanced Melanoma
David T. Pointer et al.
SURGICAL CLINICS OF NORTH AMERICA (2020)
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
Subashini Sharon Gnanendran et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Oncolytic Viruses for the Treatment of Metastatic Melanoma
Megan H. Trager et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Samantha R. Ellis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions
Cecilia A. Larocca et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature
Federica Scarfi et al.
DERMATOLOGIC THERAPY (2020)
Safety of BRAF plus MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Tomer Meirson et al.
CANCERS (2020)
Lesional therapies for in-transit melanoma
Ashlie Nadler et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Guidelines of care for the management of primary cutaneous melanoma
Susan M. Swetter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Mohd Wahid et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma
Hiromi Ogawa et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
The new paradigm of systemic therapies for metastatic melanoma
Virginia O. Volpe et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series
Nancy Rivas-Tolosa et al.
JOURNAL OF DERMATOLOGY (2016)
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Ileana S. Mauldin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Cutaneous Complications of Targeted Melanoma Therapy
Emily de Golian et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
Giuliana Carlos et al.
MELANOMA RESEARCH (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
Jennifer A. Lo et al.
JAMA ONCOLOGY (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
D. McDermott et al.
ANNALS OF ONCOLOGY (2013)
The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
Kira Minkis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy
Sofya Pintova et al.
MELANOMA RESEARCH (2013)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis
Kristin Turza et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2010)
Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod
P. A. Fanti et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2006)
Imiquimod for actinic keratosis: Systematic review and meta-analysis
Gina Hadley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Share Paper
